Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 3/20 | 0.63 |
| ▸ | MMP8 | P22894 | 3/20 | 0.63 |
| ▸ | MMP14 | P50281 | 1/20 | 0.63 |
| ▸ | PYGL | P06737 | 11/20 | 0.52 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14513403 | 1.00 | MMP9 (0.63) | MMP9MMP8MMP14PYGLMMP3 | |
| SCHEMBL7206070 | 0.96 | MMP9 (0.59) | MMP9MMP8MMP14PYGLMMP3 | |
| SCHEMBL7206063 | 0.96 | MMP9 (0.59) | MMP9MMP8MMP14PYGLMMP3 | |
| SCHEMBL7205316 | 0.93 | MMP9 (0.55) | MMP9MMP8MMP14PYGLMMP3 | |
| SCHEMBL7205323 | 0.93 | MMP9 (0.55) | MMP9MMP8MMP14PYGLMMP3 | |
| SCHEMBL7203005 | 0.93 | MMP9 (0.55) | MMP9MMP8MMP14PYGLMMP3 | |
| SCHEMBL7203001 | 0.93 | MMP9 (0.55) | MMP9MMP8MMP14PYGLMMP3 | |
| SCHEMBL7203966 | 0.91 | MMP9 (0.53) | MMP9MMP8MMP14PYGLMMP3 | |
| SCHEMBL7203960 | 0.91 | MMP9 (0.53) | MMP9MMP8MMP14PYGLMMP3 | |
| Hydrochloric Acid SCHEMBL8199774 | 0.89 | MMP9 (0.51) | MMP9MMP8MMP14PYGLMMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123483-A1 | Method and composition for treating obesity by targeting cathespin | NMPI, LLC | 2007-05-31 | — | — | US | disclosed |
| US-20060216297-A1 | Method and composition for reducing blood sugar levels or fat storage by targeting cathepsin | WILSON SONSINI GOODRICH & ROSATI, PC | 2006-09-28 | — | — | US | disclosed |
| US-20040009891-A1 | Method and composition for treating obesity by targeting cathepsin | NEWMILLENNIUM PHARMACEUTICAL, INC. | 2004-01-15 | — | — | US | disclosed |
| US-6620844-B2 | Treating obesity and non-insulin-dependent (type II) diabetes mellitus (NIDDM) by specifically targeting the genes and gene products of cathepsins | NEWMILLENNIUM PHARMACEUTICAL, INC. | 2003-09-16 | — | — | US | disclosed |
| US-20030054984-A1 | Method for reducing blood insulin levels by reducing in vivo cathepsin L activity | WILSON SONSINI GOODRICH & ROSATI, PC | 2003-03-20 | — | — | US | disclosed |
| US-20030050260-A1 | Method for treating diabetes by reducing in vivo cathepsin L activity | NMPI, LLC | 2003-03-13 | — | — | US | disclosed |
| WO-2002064613-A1 | GENETIC THERAPEUTICS FOR OBESITY AND DIABETES BY TARGETING CATHEPSIN | NEWMILLENNIUM PHARMACEUTICAL, INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030054984-A1 | Method for reducing blood insulin levels by reducing in vivo cathepsin L activity | CTSK, CTSB, CTSS | MMP9 294/4885MMP8 119/4885MMP14 715/4885 |
| US-20070123483-A1 | Method and composition for treating obesity by targeting cathespin | CTSS, PRKCSH, CTSG | MMP9 831/4885MMP8 694/4885MMP14 227/4885 |
| US-20030050260-A1 | Method for treating diabetes by reducing in vivo cathepsin L activity | CTSK, CTSS, CTSV | MMP9 124/4885MMP8 63/4885MMP14 186/4885 |
| US-20060216297-A1 | Method and composition for reducing blood sugar levels or fat storage by targeting cathepsin | CTSK, CTSS, CTSG | MMP9 205/4885MMP8 224/4885MMP14 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.